Galia Inbar - Mar 3, 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Signature
/s/ Dov Bergwerk as attorney-in-fact for Galia Inbar
Stock symbol
TEVA
Transactions as of
Mar 3, 2023
Transactions value $
$0
Form type
4
Date filed
3/7/2023, 03:08 PM
Previous filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +20.1K +99.57% 40.3K Mar 4, 2023 Direct F1, F2
transaction TEVA Ordinary Shares Options Exercise +5.71K +14.17% 46K Mar 5, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +59.8K $0.00 59.8K Mar 3, 2023 Ordinary Shares 59.8K Direct F1, F2, F3
transaction TEVA Restricted Share Units Options Exercise $0 -20.1K -25% $0.00 60.3K Mar 4, 2023 Ordinary Shares 20.1K Direct F1, F2, F4
transaction TEVA Restricted Share Units Options Exercise $0 -5.71K -33.33% $0.00 11.4K Mar 5, 2023 Ordinary Shares 5.71K Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.
F4 Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025, and March 4, 2026.
F5 Restricted share units were granted on March 5, 2021, with 5,710 vested on each of March 5, 2022 and March 5, 2023, 5,710 vesting on March 5, 2024, and 5,712 vesting on March 5, 2025.

Remarks:

EVP, Chief Human Resources Officer and Corporate Affairs